The Permanent Colostomy Population in Europe and The United States : Epidemiology, Modelling Framework, Health-Economic Burden, and Strategic Implications for Continence-Focused Innovation

Approximately 700,000 individuals in Europe and 800,000–1,000,000 in the United States live with a stoma. Colostomies represent 50–60% of these, and 40–60% are permanent end colostomies. Advances in modern colorectal cancer therapy (biologics, targeted agents, immunotherapy) have significantly increased long-term survival, resulting in a stable and expanding population of permanent colostomy survivors. Quality-of-life impairment persists in 20–30%. More than 95% of stoma-care expenditure remains focused on pouching systems, while continence-focused innovation has stagnated. This paper incorporates a structured modelling framework, uncertainty analysis, key epidemiologic parameters, and an expanded health-economic section. The refined projection confirms that permanent colostomy survivorship represents a large, predictable, chronically underserved population with clear unmet needs and strong rationale for continence-focused technological development.